Premier Research Re-brands its Medical Device Business Unit to D-TARGET
Premier Research Group announces the re-branding of its Medical Device business unit to D-TARGET, a Premier Research Company. With the continued growth in clinical development activity driven by rising regulatory and commercial demands in the medical device industry, Premier Research recognizes this sector has specific needs.
D-TARGET was founded in 1997 and acquired by Premier Research in 2007. By reintroducing the name, Premier Research reinforces its focus on this sector and highlights the capability, expertise, and experience gained by its staff operating as a dedicated Medical Device Contract Research Organization.
This division offers a team of medical device specialists with experience in the European Union and North America. D-TARGET’s staff is located in more than 30 countries with primary offices in Yverdon, Switzerland and Boston, Massachusetts. Sponsors directly benefit from regional employees with their knowledge of the local clinical research environment and ability to communicate with investigators and regulatory bodies in their own local language.
D-TARGET continues to offer a total life cycle partnership for developers of medical device and combination products, ranging from: strategic and tactical advisory services, clinical trial set-up, and clinical trial operations through to post marketing surveillance and registry support. In conjunction with the clinical operational staff, D-TARGET has specialist support groups dedicated to: regulatory affairs, ethical committee, competent authority, and country specific submissions, protocol writing, statistical analysis, and data management, thereby enabling our teams to meet the full range of needs of medical device developers worldwide.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
